NDC 0002-1457

MOUNJARO

Tirzepatide

MOUNJARO is a Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Eli Lilly And Company. The primary component is Tirzepatide.

• Product ID: 0002-1457_47ab0499-a914-4b28-8649-e7e7a6e6912b
• NDC: 0002-1457
• Product Type: Human Prescription Drug
• Proprietary Name: MOUNJARO
• Generic Name: Tirzepatide
• Dosage Form: Injection, Solution
• Route of Administration: SUBCUTANEOUS
• Marketing Start Date: 2022-05-13
• Marketing Category: NDA /
• Application Number: NDA215866
• Labeler Name: Eli Lilly and Company
• Substance Name: TIRZEPATIDE
• Active Ingredient Strength: 15 mg/.5mL
• NDC Exclude Flag: N
• Listing Certified Through: 2023-12-31

Packaging

NDC 0002-1457-80

4 SYRINGE in 1 CARTON (0002-1457-80) > .5 mL in 1 SYRINGE (0002-1457-01)

• Marketing Start Date: 2022-05-13
• NDC Exclude Flag: N
• Sample Package?: N

Drug Details

NDC Crossover Matching brand name "MOUNJARO" or generic name "Tirzepatide"

NDC	Brand Name	Generic Name
0002-1457	MOUNJARO	tirzepatide
0002-1460	MOUNJARO	tirzepatide
0002-1471	MOUNJARO	tirzepatide
0002-1484	MOUNJARO	tirzepatide
0002-1495	MOUNJARO	tirzepatide
0002-1506	MOUNJARO	tirzepatide